Tirzepatide's dual GIP/GLP-1 mechanism produces ~20–22% weight loss (SURMOUNT-1) vs semaglutide's ~15% (STEP-1) — a consistent 5–7 percentage point advantage. This guide covers the mechanism difference, week-by-week timeline, nausea comparison, and cardiovascular outcome data.
| Timepoint | Tirzepatide | Semaglutide |
|---|---|---|
| Week 4 | ~2–3% | ~2–3% |
| Week 12 | ~6–8% | ~5–7% |
| Week 24 | ~12–14% | ~9–11% |
| Week 36 | ~16–18% | ~12–14% |
| Week 52 | ~18–20% | ~13–15% |
| Week 68–72 | ~20–22% (SURMOUNT-1) | ~15% (STEP-1) |
| Parameter | Tirzepatide | Semaglutide |
|---|---|---|
| Receptor mechanism | GLP-1 + GIP (dual agonist) | GLP-1 mono-agonist |
| Average weight loss (max dose) | ~20–22% (15 mg, SURMOUNT-1) | ~15% (2.4 mg, STEP-1) |
| Average weight loss (mid dose) | ~17–19% (10 mg, SURMOUNT-1) | ~10–14% (1–2 mg, Ozempic) |
| Phase 3 trial (obesity) | SURMOUNT-1 (72 weeks) | STEP-1 (68 weeks) |
| Titration period | ~20 weeks to 15 mg | 16–20 weeks to 2.4 mg |
| Nausea rate (therapeutic dose) | 33–45% | 30–44% |
| GI discontinuation rate | ~5–8% | ~5–8% |
| Half-life | ~5 days (weekly injection) | ~7 days (weekly injection) |
| FDA obesity approval | Zepbound (Nov 2023) | Wegovy (Jun 2021) |
| Cardiovascular outcome data | SURPASS-CVOT (ongoing) | SELECT trial (20% CV risk ↓) |
| Long-term safety data | 3+ years real-world data | 5+ years real-world data |
| Research-grade availability | Available (Purgo Labs) | Available (Purgo Labs) |
Yes. Tirzepatide consistently produces greater average weight loss than semaglutide across clinical trial data. Tirzepatide 15 mg (Zepbound/Mounjaro) produced ~20–22% mean body weight reduction at 72 weeks in SURMOUNT-1, compared to semaglutide 2.4 mg (Wegovy) ~15% at 68 weeks in STEP-1. In the direct head-to-head SURPASS-2 trial, tirzepatide 15 mg outperformed semaglutide 1 mg (Ozempic) by approximately 2.4× in weight reduction (−11.2 kg vs −4.5 kg). The advantage is driven by tirzepatide's dual GLP-1/GIP agonism.
In Phase 3 trials, tirzepatide 15 mg (Zepbound) produces approximately 5–7 percentage points more weight loss than semaglutide 2.4 mg (Wegovy): ~20–22% vs ~15%. In absolute terms, for a 100 kg person, that translates to ~20–22 kg vs ~15 kg lost. The gap widens after week 24 as both compounds reach maintenance doses. Note: SURMOUNT-1 and STEP-1 are not direct head-to-head trials — they differ in population, duration, and baseline BMI.
For average weight loss, yes — tirzepatide (Zepbound 15 mg) produces ~20–22% body weight reduction vs Wegovy's ~15% in their respective Phase 3 trials. However, Wegovy has a cardiovascular outcome advantage: the SELECT trial showed a 20% reduction in major cardiovascular events in adults with obesity and established CVD. Tirzepatide's cardiovascular outcome data (SURPASS-CVOT) is still being analyzed. The SUMO trial (direct Zepbound vs Wegovy head-to-head) is ongoing and will provide definitive comparative data.
Tirzepatide is a dual GLP-1/GIP receptor agonist, while semaglutide is a pure GLP-1 agonist. GIP receptor activation adds several effects beyond GLP-1: enhanced insulin secretion from beta cells, possible direct adipose tissue effects reducing fat storage, and modulation of GLP-1 receptor sensitivity that may reduce GI side effects. The combined receptor activation appears to produce additive or synergistic weight loss effects. Interestingly, GIP receptor activation alone does not produce significant weight loss — the combination with GLP-1 agonism is what drives the superior efficacy.
Tirzepatide has a nausea rate of ~33–45% at therapeutic doses, while semaglutide has ~30–44%. Despite producing more weight loss, tirzepatide's nausea rate is similar to or slightly lower than semaglutide — likely due to GIP receptor modulation reducing GI sensitivity. GI discontinuation rates are similar for both (~5–8%). Both require slow titration protocols over 16–20 weeks to manage GI tolerance.
In the SURPASS-2 direct head-to-head trial, tirzepatide 15 mg produced ~2.4× more weight loss than Ozempic 1 mg (−11.2 kg vs −4.5 kg). Even tirzepatide 5 mg outperformed Ozempic 1 mg. Ozempic is approved at up to 2 mg for T2D, producing ~6–8% weight loss. Wegovy (semaglutide 2.4 mg) narrows the gap to ~15% vs tirzepatide's ~20–22%, but tirzepatide still leads.
Yes. Research-grade tirzepatide is available from verified suppliers like Purgo Labs for in vitro and preclinical research purposes. This is distinct from FDA-approved Mounjaro and Zepbound, which require a prescription. Purgo Labs' research-grade tirzepatide comes with third-party COAs from accredited US labs confirming ≥99% purity.
Purgo Labs provides pharmaceutical-grade tirzepatide and semaglutide with third-party COAs confirming ≥99% purity. Use code HEALTH for 15% off.
Shop Purgo LabsUse code HEALTH for 15% off · Research use only · Not for human use
Medical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.